Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: A prospective, randomized, double-blind, multicenter study

Haematologica

Volumn 91, Issue 8, 2006, Pages 1027-1032

  Abgrall, Jean François ^a,b   Guibaud, Isabelle ^a   Bastie, Jean Noël ^a   Flesch, Michel ^a   Rossi, Jean François ^a   Lacotte Thierry, Laurence ^a   Boyer, Françoise ^a   Casassus, Philippe ^a   Slama, Borhane ^a   Berthou, Christian ^a   Rodon, Philippe ^a   Leporrier, Michel ^a   Villemagne, Bruno ^a   Himberlin, Chantal ^a   Ghomari, Kamel ^a   Larosa, Fabrice ^a   Rollot, Florence ^a   Dugay, Jacqueline ^a   Allard, Christian ^a   Maigre, Michel ^a   Isnard, Françoise ^a   Zerbib, Robert ^a   Cauvin, Jean Michel ^a   more..

^a Groupe Ouest Est Leucémies et Maladies du Sang GOELAMS   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Anemia; Myelofibrosis; Placebo; Randomized trial; Thalidomide

Indexed keywords

ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HYDROXYUREA; PIPOBROMAN; PLACEBO; STEROID; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; DRY SKIN; ECHOGRAPHY; EDEMA; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MULTICENTER STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; NEUROPATHY; OUTCOME ASSESSMENT; OUTPATIENT; PARESTHESIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SOMNOLENCE; SPLEEN SIZE; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ANGIOGENESIS INHIBITORS; DOUBLE-BLIND METHOD; FRANCE; HUMANS; MYELOFIBROSIS; MYELOID METAPLASIA; PLACEBOS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; THALIDOMIDE;

EID: 33746989740     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol 1995;22:327.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-70
3. Tefferi A. Myelofibrosis with myeloid Metaplasia. N Engl J Med 2000;342:1255-65.
4. Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. The Oncologist 2003;8:225-31.
5. Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116:576-81.
6. Thiele J, Rompcik V, Wagner S, Fisher R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 1992;80:227-34.
7. Mesa RA, Hanson CA, Raikumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-80.
8. Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A. Bone Marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 2004;89:1454-8.
9. Raje N, Anderson K. Thalidomide-a revival story. N Engl J Med 1999;341:1606-9.
10. Kantarjian H. Angiogenesis in acute myeloid leukemia and treatment of AML and myelofibrosis with thalidomide. ASH 41st annual meeting, 1999, New Orleans, LA, USA.
11. st annual meeting, 1999. New Orleans, LA, USA.
12. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis and myeloid metaplasia. Br J Haematol 2001;114:78-83.
13. Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001;115:301-15.
14. Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica 2001;86:772-3.
15. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-96.
16. Giovanni B, Michelle E, Letizia C, Filippo B, Pier Paolo P, Giuseppe V, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from 5 studies. Leuk Lymphoma 2002;43:2301-7.
17. Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609-14.
18. Strupp C, Germing U, Scherer A, Kundgen A, Modder U, Gattermann N, et al. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 2004;72:52-7.
19. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004;22:424-31.
20. Merup M, Kutti J, Birgergard G, Mauritzson N, Bjorkholm M, Markevarn B, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis and myeloid metaplasia. Swedish National Study Group on Chronic Myeloproliferative Disorders. Med Oncol 2002;19:79-86.
21. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, et al. A phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis withn myeloid metaplasia. Blood 2003;101:2534-41.
22. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004;79:883-9.
23. Berlin NI. Polycythemia vera: diagnosis and treatment 2002. Expert Rev Anticancer Ther 2002;2:330-6.
24. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report of 195 cases with a new scoring system. Blood 1996;88:1013-8.